# Jason Karlawish

#### List of Publications by Citations

Source: https://exaly.com/author-pdf/5688512/jason-karlawish-publications-by-citations.pdf

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

105<br/>papers5,382<br/>citations25<br/>h-index73<br/>g-index115<br/>ext. papers7,416<br/>ext. citations6<br/>avg, IF5.84<br/>L-index

#	Paper	IF	Citations
105	NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer</i> and <i>Dementia</i> , <b>2018</b> , 14, 535-562	1.2	3155
104	The A4 study: stopping AD before symptoms begin?. Science Translational Medicine, 2014, 6, 228fs13	17.5	455
103	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. <i>Alzheimer</i> and Dementia, <b>2014</b> , 10, 477-484.e1	1.2	118
102	Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. <i>Neurology</i> , <b>2011</b> , 77, 1487-93	6.5	89
101	APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts. <i>PLoS Medicine</i> , <b>2017</b> , 14, e1002254	11.6	86
100	Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. <i>Alzheimeros Research and Therapy</i> , <b>2015</b> , 7, 26	9	80
99	Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. <i>Npj Parkinson Disease</i> , <b>2018</b> , 4, 19	9.7	72
98	Alzheimer's disease: The next frontier-Special Report 2017. Alzheimera and Dementia, 2017, 13, 374-38	01.2	60
97	Cognitive aging: a report from the Institute of Medicine. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 2121-2	27.4	56
96	Cognitive, social, and neural determinants of diminished decision-making and financial exploitation risk in aging and dementia: A review and new model. <i>Journal of Elder Abuse and Neglect</i> , <b>2016</b> , 28, 320-2	3 <i>4</i> 49	52
95	The views of Alzheimer disease patients and their study partners on proxy consent for clinical trial enrollment. <i>American Journal of Geriatric Psychiatry</i> , <b>2008</b> , 16, 240-7	6.5	47
94	How redesigning AD clinical trials might increase study partners' willingness to participate. <i>Neurology</i> , <b>2008</b> , 71, 1883-8	6.5	47
93	Statin Therapy and Risk of Acute Memory Impairment. <i>JAMA Internal Medicine</i> , <b>2015</b> , 175, 1399-405	11.5	46
92	Awareness of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia Diagnoses Associated With Lower Self-Ratings of Quality of Life in Older Adults. <i>Journals of Gerontology -</i> <i>Series B Psychological Sciences and Social Sciences</i> , <b>2017</b> , 72, 974-985	4.6	45
91	The relative contributions of disease label and disease prognosis to Alzheimer's stigma: A vignette-based experiment. <i>Social Science and Medicine</i> , <b>2015</b> , 143, 117-27	5.1	44
90	African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials. <i>Alzheimer and Dementia: Translational Research and Clinical Interventions</i> , <b>2017</b> , 3, 57-64	6	43
89	Relationships Between Cognitive Complaints and Quality of Life in Older Adults With Mild Cognitive Impairment, Mild Alzheimer Disease Dementia, and Normal Cognition. <i>Alzheimer Disease and Associated Disorders</i> , <b>2018</b> , 32, 276-283	2.5	43

## (2020-2015)

88	Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials. <i>Neurology</i> , <b>2015</b> , 84, 1488-94	6.5	37
87	Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults. <i>JAMA Neurology</i> , <b>2018</b> , 75, 44-50	17.2	34
86	Interpreting the clinical significance of capacity scores for informed consent in Alzheimer disease clinical trials. <i>American Journal of Geriatric Psychiatry</i> , <b>2008</b> , 16, 568-74	6.5	34
85	A Trial of Financial and Social Incentives to Increase Older Adults' Walking. <i>American Journal of Preventive Medicine</i> , <b>2017</b> , 52, e123-e130	6.1	31
84	Ascertaining Subjective Cognitive Decline: A Comparison of Approaches and Evidence for Using an Age-Anchored Reference Group. <i>Journal of Alzheimeros Disease</i> , <b>2015</b> , 48 Suppl 1, S43-55	4.3	31
83	Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results. <i>PLoS ONE</i> , <b>2020</b> , 15, e0229137	3.7	30
82	Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. <i>Alzheimer and Dementia</i> , <b>2016</b> , 12, 614-22	1.2	30
81	A review of ethical issues in dementia. <i>International Psychogeriatrics</i> , <b>2015</b> , 27, 1635-47	3.4	28
80	Identifiable Characteristics and Potentially Malleable Beliefs Predict Stigmatizing Attributions Toward Persons With Alzheimer's Disease Dementia: Results of a Survey of the U.S. General Public. <i>Health Communication</i> , <b>2018</b> , 33, 264-273	3.2	25
79	Supported Decision Making With People at the Margins of Autonomy. <i>American Journal of Bioethics</i> , <b>2021</b> , 21, 4-18	1.1	25
78	What features of stigma do the public most commonly attribute to Alzheimer's disease dementia? Results of a survey of the U.S. general public. <i>Alzheimer</i> and Dementia, <b>2018</b> , 14, 925-932	1.2	24
77	Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials. <i>Neurobiology of Aging</i> , <b>2016</b> , 39, 147-53	5.6	22
76	GeneMatch: A novel recruitment registry using at-home APOE genotyping to enhance referrals to Alzheimer's prevention studies. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 515-524	1.2	21
75	Ethics of reallocating ventilators in the covid-19 pandemic. <i>BMJ, The</i> , <b>2020</b> , 369, m1828	5.9	21
74	Cognitive correlates of metamemory in Alzheimer's disease. <i>Neuropsychology</i> , <b>2014</b> , 28, 695-705	3.8	18
73	Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. <i>JAMA Neurology</i> , <b>2020</b> , 77, 1504-1513	17.2	18
72	What Latino Puerto Ricans and non-Latinos say when they talk about Alzheimer's disease. <i>Alzheimer</i> and Dementia, <b>2011</b> , 7, 161-70	1.2	17
71	The Collaborative Aging Research Using Technology Initiative: An Open, Sharable, Technology-Agnostic Platform for the Research Community. <i>Digital Biomarkers</i> , <b>2020</b> , 4, 100-118	7.1	16

70	Paradoxical lucidity: A potential paradigm shift for the neurobiology and treatment of severe dementias. <i>Alzheimer and Dementia</i> , <b>2019</b> , 15, 1107-1114	1.2	15
69	Study partners should be required in preclinical Alzheimer's disease trials. <i>Alzheimer Research and Therapy</i> , <b>2017</b> , 9, 93	9	15
68	International drive to illuminate delirium: A developing public health blueprint for action. <i>Alzheimer</i> and Dementia, <b>2020</b> , 16, 711-725	1.2	14
67	Advances in Alzheimer's imaging are changing the experience of Alzheimer's disease. <i>Alzheimer</i> and Dementia: Diagnosis, Assessment and Disease Monitoring, <b>2018</b> , 10, 285-300	5.2	14
66	Is the WHO Definition of Health Aging Well? Frameworks for "Health" After Three Score and Ten. <i>American Journal of Public Health</i> , <b>2019</b> , 109, 1104-1106	5.1	14
65	Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. <i>Alzheimer</i> and Dementia, <b>2016</b> , 12, 510-5	1.2	14
64	Patient and Physician Views about Protocolized Dialysis Treatment in Randomized Trials and Clinical Care. <i>AJOB Empirical Bioethics</i> , <b>2016</b> , 7, 106-115	3	14
63	Examining the Pathways Between Self-Awareness and Well-Being in Mild to Moderate Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , <b>2015</b> , 23, 1297-1306	6.5	12
62	Study partners perform essential tasks in dementia research and can experience burdens and benefits in this role. <i>Dementia</i> , <b>2016</b> ,	3	12
61	The Proactive Patient: Long-Term Care Insurance Discrimination Risks of Alzheimer's Disease Biomarkers. <i>Journal of Law, Medicine and Ethics</i> , <b>2018</b> , 46, 485-498	1.2	12
60	Researchers' perspectives on the role of study partners in dementia research. <i>International Psychogeriatrics</i> , <b>2014</b> , 26, 1649-57	3.4	12
59	Alzheimer's Prevention Initiative Generation Program: Development of an genetic counseling and disclosure process in the context of clinical trials. <i>Alzheimer</i> and Dementia: Translational Research and Clinical Interventions, <b>2019</b> , 5, 705-716	6	12
58	Alive inside. <i>Bioethics</i> , <b>2020</b> , 34, 295-305	2	12
57	The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA. <i>Nature Reviews Neurology</i> , <b>2021</b> , 17, 523-524	15	12
56	Preclinical Alzheimer Disease and the Dawn of the Pre-Caregiver. <i>JAMA Neurology</i> , <b>2019</b> , 76, 631-632	17.2	11
55	Cognitive Impairment Evaluation and Management. <i>Medical Clinics of North America</i> , <b>2020</b> , 104, 807-82	5 <sub>7</sub>	11
54	Attitudes Toward Physician-Assisted Death From Individuals Who Learn They Have an Alzheimer Disease Biomarker. <i>JAMA Neurology</i> , <b>2019</b> , 76, 864-866	17.2	9
53	Research consent capacity varies with executive function and memory in Parkinson's disease.  Movement Disorders, 2016, 31, 414-7	7	9

## (2021-2010)

52	Desktop medicine. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 304, 2061-2	27.4	9
51	Modification of everyday activities and its association with self-awareness in cognitively diverse older adults. <i>PLoS ONE</i> , <b>2019</b> , 14, e0222769	3.7	7
50	Randomized evaluation of trial acceptability by INcentive (RETAIN): Study protocol for two embedded randomized controlled trials. <i>Contemporary Clinical Trials</i> , <b>2019</b> , 76, 1-8	2.3	7
49	Caregiving at a Physical Distance: Initial Thoughts for COVID-19 and Beyond. <i>Journal of the American Geriatrics Society</i> , <b>2020</b> , 68, 1170-1172	5.6	7
48	'That would be dreadful': The ethical, legal, and social challenges of sharing your Alzheimer's disease biomarker and genetic testing results with others. <i>Journal of Law and the Biosciences</i> , <b>2021</b> , 8, lsab004	4.1	7
47	Parkinsonian signs are a risk factor for falls. <i>Gait and Posture</i> , <b>2017</b> , 55, 1-5	2.6	5
46	Expanding engagement with the ethical implications of changing definitions of Alzheimer's disease. <i>Lancet Psychiatry,the</i> , <b>2017</b> , 4, e6-e7	23.3	5
45	Identifying an appropriate measurement modeling approach for the Mini-Mental State Examination. <i>Psychological Assessment</i> , <b>2016</b> , 28, 125-33	5.3	5
44	Policy statement on voting by persons with dementia residing in long-term care facilities. <i>Alzheimer</i> and Dementia, <b>2006</b> , 2, 243-5	1.2	5
43	The Future Is P-Tau-Anticipating Direct-to-Consumer Alzheimer Disease Blood Tests. <i>JAMA Neurology</i> , <b>2021</b> , 78, 379-380	17.2	5
42	The Interview for Decisional Abilities (IDA): a tool to assess the decisional capacity of abused and neglected older adults. <i>Journal of Elder Abuse and Neglect</i> , <b>2019</b> , 31, 244-254	1.9	4
41	Ethical and Regulatory Issues for Embedded Pragmatic Trials Involving People Living with Dementia. <i>Journal of the American Geriatrics Society</i> , <b>2020</b> , 68 Suppl 2, S37-S42	5.6	4
40	Rescuing Research Participants After Alzheimer Trials Stop Early: Sending Out an SOS. <i>JAMA Neurology</i> , <b>2020</b> , 77, 413-414	17.2	4
39	Unfinished Business in Preventing Alzheimer Disease. <i>JAMA Internal Medicine</i> , <b>2016</b> , 176, 1739-1740	11.5	4
38	Willingness to participate in pragmatic dialysis trials: the importance of physician decisional autonomy and consent approach. <i>Trials</i> , <b>2017</b> , 18, 474	2.8	3
37	Prognosis Communication in Late-Life Disability: A Mixed Methods Study. <i>Journal of the American Geriatrics Society</i> , <b>2017</b> , 65, 2496-2501	5.6	3
36	Implications of FDA Approval of a First Disease-Modifying Therapy for a Neurodegenerative Disease on the Design of Subsequent Clinical Trials. <i>Neurology</i> , <b>2021</b> , 97, 496-500	6.5	3
35	What is paradoxical lucidity? The answer begins with its definition. Alzheimera and Dementia, 2021,	1.2	3

34	Aducanumab and the Business of Alzheimer Disease-Some Choice. <i>JAMA Neurology</i> , <b>2021</b> , 78, 1303-130	<b>4</b> 17.2	3
33	Application of In-Home Monitoring Data to Transition Decisions in Continuing Care Retirement Communities: Usability Study. <i>Journal of Medical Internet Research</i> , <b>2021</b> , 23, e18806	7.6	3
32	Effects of Self-Identification as a Caregiver on Expectations of Public Stigma of Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , <b>2021</b> , 5, 31-39	3.3	3
31	Bioethical Issues in Pharmacoepidemiologic Research <b>2012</b> , 623-639		2
30	Disclosing Genetic Risk of Alzheimer's Disease to Cognitively Unimpaired Older Adults: Findings from the Study of Knowledge and Reactions to APOE Testing (SOKRATES II). <i>Journal of Alzheimeras Disease</i> , <b>2021</b> , 84, 1015-1028	4.3	2
29	"I Don't Have Time to Sit and Talk with Them": Hospitalists' Perspectives on Palliative Care Consultation for Patients with Dementia. <i>Journal of the American Geriatrics Society</i> , <b>2020</b> , 68, 2365-2372	5.6	2
28	Family members' perspectives on learning cognitively unimpaired older adults' amyloid-IPET scan results. <i>Journal of the American Geriatrics Society</i> , <b>2021</b> , 69, 3203-3211	5.6	2
27	Research Attitudes Questionnaire scores predict Alzheimer's disease clinical trial dropout. <i>Clinical Trials</i> , <b>2021</b> , 18, 237-244	2.2	2
26	Effectiveness and Ethics of Incentives for Research Participation: 2 Randomized Clinical Trials. JAMA Internal Medicine, <b>2021</b> , 181, 1479-1488	11.5	2
25	A Typical Day With Mild Cognitive Impairment. <i>American Journal of Public Health</i> , <b>2017</b> , 107, 927-928	5.1	1
24	The relative contributions of biomarkers, disease modifying treatment, and dementia severity to Alzheimer's stigma: A vignette-based experiment. <i>Social Science and Medicine</i> , <b>2021</b> , 292, 114620	5.1	1
23	Where Do You End, and I Begin? How Relationships Confound Advance Directives in the Care of Persons Living with Dementia. <i>American Journal of Bioethics</i> , <b>2020</b> , 20, 83-85	1.1	1
22	Participation of persons with dementia and their caregivers in research. <i>Journal of the American Geriatrics Society</i> , <b>2021</b> , 69, 1784-1792	5.6	1
21	"Together Make a Visit; Together Make a Plan": Messaging to Adult Children with Concerns about a Parent's Memory Loss. <i>Health Communication</i> , <b>2020</b> , 35, 512-523	3.2	1
20	Unwrapping A Fragile ConceptThe Alzheimer Conundrum By Lock Margaret Princeton (NJ) : Princeton University Press , 2014 328[pp., \$29.95 <b>2014</b> , 33, 718-719		O
19	Is there a difference between terminal lucidity and paradoxical lucidity?. <i>Alzheimer</i> and Dementia, <b>2022</b> ,	1.2	O
18	The ethical implications of paradoxical lucidity in persons with dementia. <i>Journal of the American Geriatrics Society</i> , <b>2021</b> , 69, 3617-3622	5.6	O
17	Decision-Making Capacity Will Have a Limited Effect on Civil Commitment Practices. <i>American Journal of Bioethics</i> , <b>2019</b> , 19, 86-88	1.1	

#### LIST OF PUBLICATIONS

16	P2-229: WHICH SELF-REPORTED COGNITIVE DIFFICULTIES DIFFERENTIATE COGNITIVELY NORMAL OLDER ADULTS FROM THOSE WITH MCI? <b>2014</b> , 10, P558-P559
15	P4-069: DEVELOPMENT OF A PROCESS TO DISCLOSE AMYLOID IMAGING RESULTS TO COGNITIVELY NORMAL OLDER ADULT RESEARCH PARTICIPANTS <b>2014</b> , 10, P808-P808
14	Ethical, Legal, and Social Issues in Dementia <b>2013</b> , 137-149
13	Bioethical Issues in Pharmacoepidemiologic Research <b>2013</b> , 301-310
12	Please, Don't Fly Me to the Moon. American Journal of Bioethics, <b>2021</b> , 21, 20-22
11	Developing an Economic and Policy Research Agenda for Blood Biomarkers of Neurodegenerative Diseases. <i>JAMA Health Forum</i> , <b>2021</b> , 2, e211428
10	Desktop Medicine and the Practice of Wealth Care. <i>JAMA Internal Medicine</i> , <b>2021</b> , 181, 227-228 11.5
9	Predictors of who Serves as an Alzheimer's Disease Research Participant's Study Partner and the Impact of their Relationship on Study Partners' Reports on Participants <i>Research on Aging</i> , <b>2022</b> , 16402 75221075739
8	Preliminary results from the COVID caregiving project Alzheimeros and Dementia, 2021, 17 Suppl 7, e0551299
7	Supported Decision Making with People at the Margins of Autonomy: Response to Commentaries  American Journal of Bioethics, <b>2022</b> , 22, W1-W4
6	Cognitively unimpaired adultsIreactions to disclosure of amyloid PET scan results <b>2020</b> , 15, e0229137
5	Cognitively unimpaired adults[reactions to disclosure of amyloid PET scan results <b>2020</b> , 15, e0229137
4	Cognitively unimpaired adults leactions to disclosure of amyloid PET scan results <b>2020</b> , 15, e0229137
3	Cognitively unimpaired adults[reactions to disclosure of amyloid PET scan results <b>2020</b> , 15, e0229137
2	Cognitively unimpaired adults reactions to disclosure of amyloid PET scan results <b>2020</b> , 15, e0229137
1	Cognitively unimpaired adultsDeactions to disclosure of amyloid PET scan results <b>2020</b> , 15, e0229137